May IL-17 have a role in COVID-19 infection?

Med Hypotheses. 2020 Jul:140:109749. doi: 10.1016/j.mehy.2020.109749. Epub 2020 Apr 22.

Authors

Matteo Megna¹, Maddalena Napolitano², Gabriella Fabbrocini¹

Affiliations

¹ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy.
² Department of Medicine and Health Science Vincenzo Tiberio, University of Molise, Campobasso, Italy.

No abstract available

Publication types

Letter

MeSH terms

Animals
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / complications
Coronavirus Infections / drug therapy
Coronavirus Infections / physiopathology*
Cytokine Release Syndrome / drug therapy
Cytokine Release Syndrome / etiology*
Cytokine Release Syndrome / physiopathology
Humans
Influenza, Human / physiopathology
Interleukin-17 / antagonists & inhibitors
Interleukin-17 / physiology*
Interleukin-6 / physiology
Mice
Mice, Knockout
Models, Immunological
Multiple Organ Failure / etiology
Multiple Organ Failure / prevention & control
Orthomyxoviridae Infections / physiopathology
Pandemics*
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy
Pneumonia, Viral / physiopathology*
Receptors, Interleukin-17 / deficiency
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
Il17ra protein, mouse
Interleukin-17
Interleukin-6
Receptors, Interleukin-17
ixekizumab